Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.0%

12 terminated/withdrawn out of 75 trials

Success Rate

58.6%

-27.9% vs industry average

Late-Stage Pipeline

6 trials in Phase 3/4

Results Transparency

12%

2 of 17 completed trials have results

Key Signals

26 recruiting2 with results7 withdrawn

Enrollment Performance

Analytics

N/A

14(37.8%)

Phase 2

12(32.4%)

Phase 3

5(13.5%)

Phase 1

4(10.8%)

Phase 4

1(2.7%)

Early Phase 1

1(2.7%)

37Total

N/A(14)

Phase 2(12)

Phase 3(5)

Phase 1(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (75)

Showing 20 of 75 trials

NCT06500273Phase 2Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Role: collaborator

NCT07290985Phase 2Recruiting

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

Role: collaborator

NCT07689812Not ApplicableNot Yet Recruiting

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Role: lead

NCT07718633Not ApplicableNot Yet Recruiting

Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)

Role: lead

NCT07340567Phase 3Active Not Recruiting

Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test

Role: collaborator

NCT06450314Phase 2Recruiting

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Role: collaborator

NCT07717450Phase 3Not Yet Recruiting

Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

Role: collaborator

NCT05837663Recruiting

Trifecta-Lung cfDNA-MMDx Study

Role: collaborator

NCT06529822Phase 1Recruiting

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Role: collaborator

NCT05174169Phase 2Recruiting

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Role: collaborator

NCT07339384Not ApplicableNot Yet Recruiting

Signatera Assessment in Early-Stage Endometrial Cancer

Role: lead

NCT07401316Not ApplicableRecruiting

Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

Role: collaborator

NCT07292285Withdrawn

The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.

Role: collaborator

NCT07021989Phase 2Not Yet Recruiting

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Role: collaborator

NCT04707872Recruiting

Trifecta-Heart cfDNA-MMDx Study

Role: collaborator

NCT04239703Recruiting

Trifecta-Kidney cfDNA-MMDx Study

Role: collaborator

NCT05512364Phase 3Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Role: collaborator

NCT04920032Phase 1Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Role: collaborator

NCT06808880Recruiting

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Role: lead

NCT07565857Not ApplicableNot Yet Recruiting

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

Role: lead